AgomAb Therapeutics is a newly public clinical-stage fibrosis biotech with no revenue, a Nasdaq ADS listing, an IPO-funded runway into the first half of 2029, and two 2026 data tracks that need to validate organ-restricted ALK5 inhibition.
References
Sources used in this report
SEC datasetSEC company tickers exchange datasetRetrieved 2026-05-14 · Issuer identity, exchange and CIK cross-check.SEC APIAGMB submissions APIRetrieved 2026-05-14 · Filing chronology and latest SEC filing discovery.Annual reportFY2025 Form 20-F2026-04-23 · ADS structure, pipeline, clinical data, financials, runway, risk factors, internal controls and post-IPO capitalization.Current reportApril 2026 Form 6-K2026-04-24 · Filing wrapper for FY2025 results and AGM materials.Company releaseFY2025 results and 2026 outlook release2026-04-23 · Cash position, IPO proceeds, runway, 2025 net loss, R&D expense and 2026 milestones.ProspectusIPO prospectus2026-02-06 · ADS terms, use of proceeds, pipeline positioning, market context and risk factors.Company releaseIPO closing release2026-02-09 · IPO closing date, ADS trading start and gross proceeds.Company releaseIPO pricing release2026-02-05 · IPO price, ADS count, Nasdaq ticker and expected gross proceeds.Company websiteAgomab pipeline pageRetrieved 2026-05-14 · Current company pipeline framing for ontunisertib, AGMB-447 and AGMB-101.Clinical-trial registryClinicalTrials.gov STENOVA recordRetrieved 2026-05-14 · Trial design, status, enrollment, dates and sponsor for ontunisertib in fibrostenosing Crohn's disease.Clinical-trial registryClinicalTrials.gov AGMB-447 recordRetrieved 2026-05-14 · Phase 1 AGMB-447 design, status, enrollment, dates and IPF patient component.Regulator contextFDA Step 3: Clinical Research2018-01-04 · Neutral context for clinical trial phase progression and IND process.